Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer
Description:
A webinar series that provides an overview of molecular genetic testing methods and current best practices for HR+/HER2- breast cancer, emphasizing mutations in PIK3CA, AKT1, PTEN, and ESR1.
Learning Objectives:
- Recognize the importance of mutation testing for patients with HR+/HER2- metastatic breast cancer
- Describe best practices for molecular testing in metastatic breast cancer
Working Group:
Katherine B. Geiersbach, M.D. (chair)
Mayo Clinic
Karthik Giridhar, M.D.
Mayo Clinic
Shuko Harada, M.D.
University of Alabama at Birmingham
Eric Vail, M.D.
Cedars-Sinai Medical Center
Paul M. Waring, MBBS, Ph.D.
Translational Pathology Consulting Services
This webinar series is planned and coordinated by the Metastatic Breast Cancer Webinar Series Working Group, and supported by the AMP Training & Education Committee.
Duration: three 1-hour webinars
Target Audience: Molecular pathologists, surgical pathologists, clinical oncologists, trainees, laboratory technical staff, and clinicians.
Live Webinars: October 21, 2025 | 4PM ET
October 27, 2025 | 4PM ET
October 30, 2025 | 2PM ET
Certificate: Learners will be awarded a Certificate of Attendance at the conclusion of the course. CME or CMLE credits are NOT available for this education series.
This activity was funded by AstraZeneca.
